Cancer Cell Line-specific Protein Profiles in Extracellular Vesicles Identified by Proteomics

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2020 Sep 4

PMID 32886718

Citations 16

Authors

Eduarda M Guerreiro

Reidun Ovstebo

Bernd Thiede

Daniela Elena Costea

Tine M Soland

Hilde Kanli Galtung

Affiliations

Soon will be listed here.

Abstract

Extracellular vesicles (EVs), are important for intercellular communication in both physiological and pathological processes. To explore the potential of cancer derived EVs as disease biomarkers for diagnosis, monitoring, and treatment decision, it is necessary to thoroughly characterize their biomolecular content. The aim of the study was to characterize and compare the protein content of EVs derived from three different cancer cell lines in search of a specific molecular signature, with emphasis on proteins related to the carcinogenic process. Oral squamous cell carcinoma (OSCC), pancreatic ductal adenocarcinoma (PDAC) and melanoma brain metastasis cell lines were cultured in CELLine AD1000 flasks. EVs were isolated by ultrafiltration and size-exclusion chromatography and characterized. Next, the isolated EVs underwent liquid chromatography-mass spectrometry (LC-MS) analysis for protein identification. Functional enrichment analysis was performed for a more general overview of the biological processes involved. More than 600 different proteins were identified in EVs from each particular cell line. Here, 14%, 10%, and 24% of the identified proteins were unique in OSCC, PDAC, and melanoma vesicles, respectively. A specific protein profile was discovered for each cell line, e.g., EGFR in OSCC, Muc5AC in PDAC, and FN1 in melanoma vesicles. Nevertheless, 25% of all the identified proteins were common to all cell lines. Functional enrichment analysis linked the proteins in each data set to biological processes such as "biological adhesion", "cell motility", and "cellular component biogenesis". EV proteomics discovered cancer-specific protein profiles, with proteins involved in processes promoting tumor progression. In addition, the biological processes associated to the melanoma-derived EVs were distinct from the ones linked to the EVs isolated from OSCC and PDAC. The malignancy specific biomolecular cues in EVs may have potential applications as diagnostic biomarkers and in therapy.

Citing Articles

The effect of extracellular vesicles derived from oral squamous cell carcinoma on the metabolic profile of oral fibroblasts.

Lipka A, Soland T, Nieminen A, Sapkota D, Haug T, Galtung H Front Mol Biosci. 2025; 12:1492282.

PMID: 40062228 PMC: 11885147. DOI: 10.3389/fmolb.2025.1492282.

Updates on neonatal cell and novel therapeutics: Proceedings of the Second Neonatal Cell Therapies Symposium (2024).

Paton M, Benders M, Blatch-Williams R, Dallimore E, Edwards A, Elwood N Pediatr Res. 2025; .

PMID: 39815092 DOI: 10.1038/s41390-025-03856-x.

Stabilizing milk-derived extracellular vesicles (mEVs) through lyophilization: a novel trehalose and tryptophan formulation for maintaining structure and Bioactivity during long-term storage.

Dogan A, Marsh S, Tschetter R, E Beard C, Amin M, Jourdan L J Biol Eng. 2025; 19(1):4.

PMID: 39806456 PMC: 11727230. DOI: 10.1186/s13036-024-00470-z.

Analysis of Cytotoxic Granules and Constitutively Produced Extracellular Vesicles from Large Granular Lymphocytic Leukemia Cell Lines.

Ploeger L, Kaleja P, Tholey A, Lettau M, Janssen O Cells. 2024; 13(16.

PMID: 39195200 PMC: 11353062. DOI: 10.3390/cells13161310.

Defining the Soluble and Extracellular Vesicle Protein Compartments of Plasma Using In-Depth Mass Spectrometry-Based Proteomics.

Sharma N, Angori S, Sandberg A, Mermelekas G, Lehtio J, Wiklander O J Proteome Res. 2024; 23(9):4114-4127.

PMID: 39141927 PMC: 11385381. DOI: 10.1021/acs.jproteome.4c00490.

References

Kanada M, Bachmann M, Contag C . Signaling by Extracellular Vesicles Advances Cancer Hallmarks. Trends Cancer. 2017; 2(2):84-94. DOI: 10.1016/j.trecan.2015.12.005. View

Yang J, Price M, Neudauer C, Wilson C, Ferrone S, Xia H . Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol. 2004; 165(6):881-91. PMC: 2172406. DOI: 10.1083/jcb.200403174. View

Tinder T, Subramani D, Basu G, Bradley J, Schettini J, Million A . MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol. 2008; 181(5):3116-25. PMC: 2625292. DOI: 10.4049/jimmunol.181.5.3116. View

Yuan Y, Jiang Y, Sun C, Chen Q . Role of the tumor microenvironment in tumor progression and the clinical applications (Review). Oncol Rep. 2016; 35(5):2499-515. DOI: 10.3892/or.2016.4660. View

Maas S, Breakefield X, Weaver A . Extracellular Vesicles: Unique Intercellular Delivery Vehicles. Trends Cell Biol. 2016; 27(3):172-188. PMC: 5318253. DOI: 10.1016/j.tcb.2016.11.003. View

Yang J, Price M, Li G, Bar-Eli M, Salgia R, Jagedeeswaran R . Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res. 2009; 69(19):7538-47. PMC: 2762355. DOI: 10.1158/0008-5472.CAN-08-4626. View

Pathan M, Fonseka P, Chitti S, Kang T, Sanwlani R, Van Deun J . Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. Nucleic Acids Res. 2018; 47(D1):D516-D519. PMC: 6323905. DOI: 10.1093/nar/gky1029. View

Hamada T, Wakamatsu T, Miyahara M, Nagata S, Nomura M, Kamikawa Y . MUC4: a novel prognostic factor of oral squamous cell carcinoma. Int J Cancer. 2011; 130(8):1768-76. DOI: 10.1002/ijc.26187. View

Kaur S, Kumar S, Momi N, Sasson A, Batra S . Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol. 2013; 10(10):607-20. PMC: 3934431. DOI: 10.1038/nrgastro.2013.120. View

10.

Schmidt A, Forne I, Imhof A . Bioinformatic analysis of proteomics data. BMC Syst Biol. 2014; 8 Suppl 2:S3. PMC: 4108846. DOI: 10.1186/1752-0509-8-S2-S3. View

11.

Lazar I, Clement E, Ducoux-Petit M, Denat L, Soldan V, Dauvillier S . Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines. Pigment Cell Melanoma Res. 2015; 28(4):464-75. DOI: 10.1111/pcmr.12380. View

12.

Weinstein D, Leininger J, Hamby C, Safai B . Diagnostic and prognostic biomarkers in melanoma. J Clin Aesthet Dermatol. 2014; 7(6):13-24. PMC: 4086529. View

13.

Ji H, Greening D, Barnes T, Lim J, Tauro B, Rai A . Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics. 2013; 13(10-11):1672-86. DOI: 10.1002/pmic.201200562. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Yamada N, Hamada T, Goto M, Tsutsumida H, Higashi M, Nomoto M . MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. Int J Cancer. 2006; 119(8):1850-7. DOI: 10.1002/ijc.22047. View

16.

Rosa-Fernandes L, Rocha V, Carregari V, Urbani A, Palmisano G . A Perspective on Extracellular Vesicles Proteomics. Front Chem. 2017; 5:102. PMC: 5702361. DOI: 10.3389/fchem.2017.00102. View

17.

Moschovis D, Bamias G, Delladetsima I . Mucins in neoplasms of pancreas, ampulla of Vater and biliary system. World J Gastrointest Oncol. 2016; 8(10):725-734. PMC: 5064050. DOI: 10.4251/wjgo.v8.i10.725. View

18.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

19.

Shin S, Smith J, Rezniczek G, Pan S, Chen R, Brentnall T . Unexpected gain of function for the scaffolding protein plectin due to mislocalization in pancreatic cancer. Proc Natl Acad Sci U S A. 2013; 110(48):19414-9. PMC: 3845200. DOI: 10.1073/pnas.1309720110. View

20.

Chekenya M, Krakstad C, Svendsen A, Netland I, Staalesen V, Tysnes B . The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 2008; 27(39):5182-94. PMC: 2832310. DOI: 10.1038/onc.2008.157. View